161 related articles for article (PubMed ID: 7520783)
1. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
[No Abstract] [Full Text] [Related]
2. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
[TBL] [Abstract][Full Text] [Related]
3. A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.
Croockewit AJ; Bronchud MH; Aapro MS; Bargetzi MJ; Crown J; Gratwohl A; Lange W; Ludwig H; Martinelli G; Mertelsmann R; Nuessler V; Willemze R; De Witte TJ; Zittoun R; Zwierzina H
Eur J Cancer; 1997 Oct; 33(11):1732-46. PubMed ID: 9470826
[No Abstract] [Full Text] [Related]
4. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
6. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
[TBL] [Abstract][Full Text] [Related]
7. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin].
Rodríguez JN; Prados D; Martino ML; Muñiz R
Sangre (Barc); 1993 Aug; 38(4):340-1. PubMed ID: 8235952
[No Abstract] [Full Text] [Related]
9. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
10. Trilineage response to recombinant human granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome.
Rey C; Bader-Meunier B; Tertian G; Mielot F; Tchernia G; Yver A
Am J Hematol; 1993 May; 43(1):76-7. PubMed ID: 7686335
[No Abstract] [Full Text] [Related]
11. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
Hellström-Lindberg E
Br J Haematol; 1995 Jan; 89(1):67-71. PubMed ID: 7833279
[TBL] [Abstract][Full Text] [Related]
12. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
[TBL] [Abstract][Full Text] [Related]
13. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic growth factors for the treatment of myelodysplastic syndromes.
Hast R; Bernell P
Acta Haematol Pol; 1991; 22(2):203-7. PubMed ID: 1726768
[No Abstract] [Full Text] [Related]
15. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
16. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
Leuk Res; 1996 Aug; 20(8):693-9. PubMed ID: 8913323
[TBL] [Abstract][Full Text] [Related]
17. Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.
Katayama Y; Kojima K; Omoto E; Harada M
Int J Hematol; 1996 Dec; 65(1):89-92. PubMed ID: 8990630
[TBL] [Abstract][Full Text] [Related]
18. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes.
Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
Ann Hematol; 1994 Apr; 68(4):163-6. PubMed ID: 7516190
[TBL] [Abstract][Full Text] [Related]
19. Long-term disappearance of previous chromosomal abnormalities in myelodysplastic syndromes treated with low dose cytosine arabinoside and granulocyte/macrophage-colony stimulating factor.
Sastre JL; Ulibarrena C; Bustillo M; Suárez-Gago M; García-Torremocha MS; Vázquez MO
Haematologica; 1998 Aug; 83(8):763-5. PubMed ID: 9793271
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
